Trial Profile

A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evofosfamide (Primary) ; Docetaxel; Gemcitabine; Pemetrexed
Indications Adenocarcinoma; Non-small cell lung cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Prostate cancer; Solid tumours
Focus Adverse reactions
Sponsors Threshold Pharmaceuticals

01 Jul 2014 Results published in a Threshold Pharmaceuticals Media Release.
30 May 2012 Planned end date changed from 1 Aug 2010 to 1 Jul 2012 as reported by ClinicalTrials.gov.
24 Jan 2011 Updated results from 47 patients with pancreatic cancer were presented at the ASCO Gastro Intestinal Cancers Symposium, according to a Threshold Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com